» Articles » PMID: 11834396

Quality-of-life Impact of Lower Urinary Tract Symptom Severity: Results from the Health Professionals Follow-up Study

Overview
Journal Urology
Specialty Urology
Date 2002 Feb 9
PMID 11834396
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To estimate the magnitude of the quality-of-life impact of lower urinary tract symptom (LUTS) severity using a large (n = 8406) sample of U.S. men participating in the Health Professionals Follow-up Study.

Methods: Multiple regression modeling was used to estimate the relative quality-of-life burden of different levels of LUTS severity (defined using the American Urological Association Symptom Index as none-mild symptoms, 0 to 7; low moderate, 8 to 14; high moderate, 15 to 19; and severe, 20 to 35) and to compare these with age-matched U.S. male norms. A standardized and validated measure of both LUTS severity (the American Urological Association Symptom Index) and a widely used, standardized, multidimensional measure of quality of life (Short Form 36) were used. In addition, the relative impact of severe LUTS on the quality of life was compared with that experienced for other chronic illness conditions (diabetes, angina, hypertension, gout).

Results: The results showed that high-moderate LUTS was associated with small to moderate deficits in anxious and depressed mood and poorer role functioning related to emotional problems arising from illness. Severe LUTS was associated with additional quality-of-life deficits related to vitality and the ability to work and carry out daily tasks as a result of illness. Comparisons of the severe LUTS patient group with four other chronic illness groups showed vitality/energy, in particular, but also role functioning and depressed and anxious feelings, to be poorer in the severe LUTS group.

Conclusions: Men with high-moderate and severe LUTS identified in a large U.S. cohort have a poorer health status in several important quality-of-life dimensions. The detection and effective treatment of LUTS may substantially improve the health status for these men in these dimensions.

Citing Articles

Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035.

Wei H, Zhu C, Huang Q, Yang J, Li Y, Zhang Y BMC Urol. 2025; 25(1):34.

PMID: 39972318 PMC: 11837592. DOI: 10.1186/s12894-025-01715-9.


Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990-2021.

Safiri S, Sahin F, Aletaha R, Sullman M, Shekarriz-Foumani R, Kolahi A BMC Public Health. 2025; 25(1):500.

PMID: 39920613 PMC: 11804090. DOI: 10.1186/s12889-025-21735-2.


Innovation and the Importance of Patient-Centered Treatment.

Kim S Int Neurourol J. 2025; 28(4):251-252.

PMID: 39765336 PMC: 11710954. DOI: 10.5213/inj.2424edi06.


Comparing Patient-Reported Outcomes Following the Minimally Invasive Treatment of Benign Prostatic Hyperplasia (BPH)-Related Lower Urinary Tract Symptoms: Rezum Versus UroLift.

Wong K, Kop M, Lee F Cureus. 2024; 16(11):e74532.

PMID: 39735119 PMC: 11671228. DOI: 10.7759/cureus.74532.


Trend of ambulatory benign prostatic obstruction surgeries during COVID-19 pandemic.

Qian Z, Filipas D, Beatrici E, Ye J, Cho M, Dagnino F World J Urol. 2024; 42(1):613.

PMID: 39485508 DOI: 10.1007/s00345-024-05343-0.